drugset / Trial / NCT06582732

Performance of the Travoprost Intraocular Implant

NCT06582732

Phase 2 Completed 210 enrolled Glaukos Corporation
Non-randomizedSequentialOpen-labelTreatment

Summary

To evaluate the performance of the Travoprost Intracameral Implant by determining residual drug in explanted implants of the Travoprost Intracameral Implant and by determining aqueous humor concentrations of travoprost free acid at specified timepoints post administration through 24 months

Timeline

Start
2021-03-10
Primary completion
2023-11-02
Completion
2023-11-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Travoprost Other / unclassified 75 ug Other